| Code | CSB-RA001950MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SHR-1707, targeting amyloid precursor protein (APP). APP is a type I transmembrane glycoprotein that plays critical roles in neuronal development, synaptic plasticity, and cell adhesion. Under normal physiological conditions, APP undergoes proteolytic processing through multiple pathways, but aberrant cleavage by β- and γ-secretases generates amyloid-beta (Aβ) peptides that aggregate into neurotoxic plaques. This pathological accumulation is a hallmark of Alzheimer's disease and represents a central mechanism in neurodegeneration. APP dysfunction has also been implicated in cerebral amyloid angiopathy, Down syndrome-associated dementia, and other neurodegenerative conditions.
SHR-1707 serves as the reference antibody for this biosimilar product, providing researchers with a cost-effective alternative for investigating APP biology and amyloid pathology. This antibody is valuable for studies examining APP processing mechanisms, Aβ production pathways, and therapeutic strategies targeting amyloid cascade in neurodegenerative disease models. It supports research into protein-protein interactions, cellular localization studies, and the evaluation of potential interventions in amyloid-related pathologies.
There are currently no reviews for this product.